http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#Head
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#assertion
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#provenance
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#pubinfo
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#assertion
http://purl.obolibrary.org/obo/DOID_5844
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_5844
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00669
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#association
http://www.w3.org/2000/01/rdf-schema#label
"Sumatriptan succinate tablets should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. In addition, patients with other significant underlying cardiovascular diseases should not receive sumatriptan succinate tablets. Ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks. Peripheral vascular disease includes, but is not limited to, ischemic bowel disease (see WARNINGS). Because sumatriptan succinate tablets may increase blood pressure, they should not be given to patients with uncontrolled hypertension. Concurrent administration of MAO-A inhibitors or use within 2 weeks of discontinuation of MAO-A inhibitor therapy is contraindicated (see CLINICAL PHARMACOLOGY, Drug Interactions and PRECAUTIONS, Drug Interactions). Sumatriptan succinate tablets should not be administered to patients with hemiplegic or basilar migraine. Sumatriptan succinate tablets and any ergotamine-containing or ergot-type medication (like dihydroergotamine or methysergide) should not be used within 24 hours of each other, nor should sumatriptan succinate tablets and another 5-HT 1 Sumatriptan succinate tablets are contraindicated in patients with hypersensitivity to sumatriptan or any of their components. Sumatriptan succinate tablets are contraindicated in patients with severe hepatic impairment."
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB00669
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#provenance
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#pubinfo
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#sig
http://purl.org/nanopub/x/hasSignature
MCCHwl2Tu+vZ30xzQTJam/hrgHuIma81K6HHEqJiralarr+T8c6OqCADOG4Ay7vIueCdl3looLcr0giti4YtJ45RzWzSOhYrWrGSoDgJqu6uyY4wR/wUPss4IGtIl2QBGngm1mVC0DoXHYg6ckvEJ8fr5aPYriyqTJG4k7mWaQk=
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0
http://purl.org/dc/terms/created
2021-08-23T13:07:23.811+02:00
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY